Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA) by 7.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 463,443 shares of the company’s stock after selling 34,694 shares during the quarter. Hsbc Holdings PLC owned about 0.12% of Moderna worth $55,014,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Moderna in the second quarter valued at approximately $26,000. Cedar Wealth Management LLC boosted its holdings in shares of Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after acquiring an additional 90 shares during the period. Westside Investment Management Inc. acquired a new stake in shares of Moderna in the first quarter valued at approximately $32,000. Family Firm Inc. acquired a new stake in shares of Moderna in the second quarter valued at approximately $33,000. Finally, Rise Advisors LLC boosted its holdings in shares of Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after acquiring an additional 286 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently weighed in on MRNA. Barclays decreased their price objective on Moderna from $155.00 to $125.00 and set an “overweight” rating for the company in a report on Monday, September 16th. HSBC raised Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price target for the company in a report on Wednesday, August 28th. Hsbc Global Res raised Moderna from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 28th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 price target on shares of Moderna in a report on Thursday. Finally, Jefferies Financial Group downgraded Moderna from a “buy” rating to a “hold” rating and decreased their price target for the stock from $120.00 to $65.00 in a report on Friday, September 13th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $100.44.

Insider Activity

In other news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $127.22, for a total value of $1,908,300.00. Following the completion of the transaction, the director now owns 2,284,015 shares in the company, valued at $290,572,388.30. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $127.22, for a total transaction of $1,908,300.00. Following the completion of the sale, the director now owns 2,284,015 shares in the company, valued at approximately $290,572,388.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. The disclosure for this sale can be found here. Insiders sold a total of 93,158 shares of company stock worth $11,167,312 over the last 90 days. 15.70% of the stock is currently owned by corporate insiders.

Moderna Trading Down 3.4 %

NASDAQ:MRNA opened at $65.69 on Friday. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $170.47. The stock has a market capitalization of $25.18 billion, a price-to-earnings ratio of -4.19 and a beta of 1.68. The stock has a fifty day moving average price of $90.07 and a two-hundred day moving average price of $110.76. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter last year, the business posted ($3.62) earnings per share. The business’s revenue for the quarter was down 29.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Moderna, Inc. will post -9.52 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.